Natera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 2,700 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $108.87, for a total value of $293,949.00. Following the completion of the sale, the insider now owns 301,808 shares of the company’s stock, valued at approximately $32,857,836.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Tuesday, June 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $109.66, for a total value of $296,082.00.
• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $108.30, for a total value of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $89.55, for a total value of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The shares were sold at an average price of $92.47, for a total value of $2,468,949.00.

Natera Price Performance

NASDAQ NTRA opened at $110.70 on Wednesday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $117.23. The stock’s fifty day moving average price is $105.29 and its 200-day moving average price is $86.70. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The firm had revenue of $367.70 million for the quarter, compared to analysts’ expectations of $316.31 million. During the same period in the prior year, the firm posted ($1.23) earnings per share. The company’s quarterly revenue was up 52.1% on a year-over-year basis. On average, sell-side analysts expect that Natera, Inc. will post -2.43 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Institutional investors have recently modified their holdings of the stock. RiverPark Advisors LLC purchased a new stake in shares of Natera in the fourth quarter worth $27,000. Principal Securities Inc. purchased a new stake in shares of Natera during the fourth quarter valued at $32,000. GAMMA Investing LLC boosted its position in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares during the last quarter. YHB Investment Advisors Inc. purchased a new stake in shares of Natera during the first quarter valued at $36,000. Finally, Oliver Lagore Vanvalin Investment Group boosted its position in shares of Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. The Goldman Sachs Group boosted their price objective on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a report on Friday, May 17th. BTIG Research upped their target price on Natera from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, May 13th. Jefferies Financial Group started coverage on Natera in a report on Monday, June 3rd. They set a “buy” rating and a $142.00 target price for the company. Finally, Canaccord Genuity Group upped their target price on Natera from $100.00 to $130.00 and gave the company a “buy” rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.19.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.